MaxCyte Stock

MaxCyte Stock-Based Compensation

The Stock-Based Compensation (SBC) of MaxCyte (MXCT) as of Aug 7, 2026 is 13.08 M USD. In the previous year, Stock-Based Compensation (SBC) was 13.98 M USD — a change of -6.44% (lower).

Stock-Based Compensation

13.08 MUSD

YoY

-6.44%

Last updated:

Stock-Based Compensation (SBC) of MaxCyte is 2026 13.08 M USD. Stock-Based Compensation (SBC) of MaxCyte was 2025 13.98 M USD. It decreases by -6.44% lower compared to the previous year.
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Stock-Based Compensation (SBC) of MaxCyte is 13.08 M USD in 2026.

Stock-Based Compensation (SBC) of MaxCyte changed from 13.98 M USD to 13.08 M USD, representing a -6.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s MaxCyte historically and in real time.

Access this data via the Eulerpool API

Cash Flow — MaxCyte

All Key Metrics — MaxCyte